Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
14 hedge funds and large institutions have $912K invested in Immune Pharmaceuticals Inc. in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
8% more capital invested
Capital invested by funds: $845K → $912K (+$67K)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$390K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$42K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$26.2K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$15.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$43K |
| 2 |
Goldman Sachs
New York
|
-$24.8K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$19.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.62K |
| 5 |
IFS
Ifrah Financial Services
Little Rock,
Arkansas
|
-$4K |
IMNP Hedge Fund Activity: Q4 2016 in Review
14 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q4 2016, worth a combined $912K — up 7.9% from $845K a quarter earlier.
Fund positioning in IMNP was balanced in Q4 2016: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $390K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $43K sold.
- 14 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $912K of Immune Pharmaceuticals Inc. stock for Q4 2016, up 7.9% quarter-over-quarter.
- 3 funds opened new Immune Pharmaceuticals Inc. positions in Q4 2016 and 3 closed out, a net change of 0 holders.
- The largest Immune Pharmaceuticals Inc. buyer in Q4 2016 was Vanguard Group, an estimated $390K added.
- The largest Immune Pharmaceuticals Inc. seller in Q4 2016 was Renaissance Technologies, an estimated $43K sold.
Based on aggregated 13F filings for Q4 2016.